Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite

Executive Summary

The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs

You may also be interested in...



Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products

Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23

Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products

Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23

Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well

Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period

Related Content

UsernamePublicRestriction

Register

PS048278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel